Company intelligence / Profile preview

ARMO BioSciences

Redwood City, California, United States

Ownership: Private
Development stage: Other

Overview

ARMO BioSciences developed immune-modulatory biologic therapeutics including AM0010, a long-acting recombinant human interleukin-10, and several checkpoint and cytokine programs. Its lead asset AM0010 advanced into Phase 1/2 oncology trials with evidence of immune activation and antitumor activity, but the company was acquired by Eli Lilly in 2018 before late-stage development and any approvals.[1][2][3]

Therapeutic areas: OncologyCardiovascularImmunologyOther
Modalities: BiologicRecombinant proteinMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on ARMO BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARMO BioSciences.

Explore the full profile